ImmunityBio Statistics

Total Valuation

ImmunityBio has a market cap or net worth of $2.51 billion. The enterprise value is $3.27 billion.

Market Cap	2.51B
Enterprise Value	3.27B

Important Dates

The next estimated earnings date is Monday, August 11, 2025, before market open.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

ImmunityBio has 882.62 million shares outstanding. The number of shares has increased by 30.30% in one year.

Current Share Class	882.62M
Shares Outstanding	882.62M
Shares Change (YoY)	+30.30%
Shares Change (QoQ)	+16.15%
Owned by Insiders (%)	46.13%
Owned by Institutions (%)	9.72%
Float	130.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	67.53
Forward PS	22.86
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	104.66
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.22

Current Ratio	2.22
Quick Ratio	1.61
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.15

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-55.61%
Return on Invested Capital (ROIC)	-89.75%
Return on Capital Employed (ROCE)	-123.12%
Revenue Per Employee	$45,915
Profits Per Employee	-$601,619
Employee Count	680
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	-234,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -51.29% in the last 52 weeks. The beta is -0.07, so ImmunityBio's price volatility has been lower than the market average.

Beta (5Y)	-0.07
52-Week Price Change	-51.29%
50-Day Moving Average	2.66
200-Day Moving Average	3.36
Relative Strength Index (RSI)	49.23
Average Volume (20 Days)	10,440,729

Short Selling Information

The latest short interest is 72.12 million, so 8.17% of the outstanding shares have been sold short.

Short Interest	72.12M
Short Previous Month	73.74M
Short % of Shares Out	8.17%
Short % of Float	55.09%
Short Ratio (days to cover)	6.80

Income Statement

In the last 12 months, ImmunityBio had revenue of $31.22 million and -$409.10 million in losses. Loss per share was -$0.58.

Revenue	31.22M
Gross Profit	31.16M
Operating Income	-313.42M
Pretax Income	n/a
Net Income	-409.10M
EBITDA	-296.59M
EBIT	-313.42M
Loss Per Share	-$0.58

Full Income Statement

Balance Sheet

The company has $61.59 million in cash and $822.56 million in debt, giving a net cash position of -$760.97 million or -$0.86 per share.

Cash & Cash Equivalents	61.59M
Total Debt	822.56M
Net Cash	-760.97M
Net Cash Per Share	-$0.86
Equity (Book Value)	-590.48M
Book Value Per Share	-0.69
Working Capital	59.96M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$370.16 million and capital expenditures -$6.75 million, giving a free cash flow of -$376.91 million.

Operating Cash Flow	-370.16M
Capital Expenditures	-6.75M
Free Cash Flow	-376.91M
FCF Per Share	-$0.43

Full Cash Flow Statement

Margins

Gross Margin	99.81%
Operating Margin	-1,003.83%
Pretax Margin	-1,311.30%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ImmunityBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.30%
Shareholder Yield	-30.30%
Earnings Yield	-16.32%
FCF Yield	-15.04%

Analyst Forecast

The average price target for ImmunityBio is $11.40, which is 301.41% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.40
Price Target Difference	301.41%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	142.71%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ImmunityBio has an Altman Z-Score of -17.03 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-17.03
Piotroski F-Score	3